Sarah E Rutstein1, Christopher J Sellers, Jintanat Ananworanich, Myron S Cohen. 1. aDepartment of Health Policy and Management, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA bDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA cU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring dHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland eDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA *Sarah E. Rutstein and Christopher J. Sellers contributed equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: Acute and early HIV (AHI) is a pivotal time during HIV infection, yet there remain major shortfalls in diagnosis, linkage to care, and antiretroviral therapy (ART) initiation during AHI. We introduce an AHI-specific cascade, review recent evidence pertaining to the unique challenges of AHI, and discuss strategies for improving individual and public health outcomes. RECENT FINDINGS: Presentation during AHI is common. Expanding use of fourth-generation testing and pooled nucleic acid amplification testing has led to improved AHI detection in resource-wealthy settings. Technologies capable of AHI diagnosis are rare in resource-limited settings; further development of point-of-care devices and utilization of targeted screening is needed. Rapid ART initiation during AHI limits reservoir seeding, preserves immunity, and prevents transmission. Reporting of AHI cascade outcomes is limited, but new evidence suggests that impressive rates of diagnosis, linkage to care, rapid ART initiation, and viral suppression can be achieved. SUMMARY: With advancements in AHI diagnostics and strong evidence for the therapeutic and prevention benefits of ART initiated during AHI, improving AHI cascade outcomes is both crucial and feasible. HIV guidelines should recommend diagnostic algorithms capable of detecting AHI and prescribe rapid, universal ART initiation during AHI.
PURPOSE OF REVIEW: Acute and early HIV (AHI) is a pivotal time during HIV infection, yet there remain major shortfalls in diagnosis, linkage to care, and antiretroviral therapy (ART) initiation during AHI. We introduce an AHI-specific cascade, review recent evidence pertaining to the unique challenges of AHI, and discuss strategies for improving individual and public health outcomes. RECENT FINDINGS: Presentation during AHI is common. Expanding use of fourth-generation testing and pooled nucleic acid amplification testing has led to improved AHI detection in resource-wealthy settings. Technologies capable of AHI diagnosis are rare in resource-limited settings; further development of point-of-care devices and utilization of targeted screening is needed. Rapid ART initiation during AHI limits reservoir seeding, preserves immunity, and prevents transmission. Reporting of AHI cascade outcomes is limited, but new evidence suggests that impressive rates of diagnosis, linkage to care, rapid ART initiation, and viral suppression can be achieved. SUMMARY: With advancements in AHI diagnostics and strong evidence for the therapeutic and prevention benefits of ART initiated during AHI, improving AHI cascade outcomes is both crucial and feasible. HIV guidelines should recommend diagnostic algorithms capable of detecting AHI and prescribe rapid, universal ART initiation during AHI.
Authors: Susan A Fiscus; Christopher D Pilcher; William C Miller; Kimberly A Powers; Irving F Hoffman; Matthew Price; David A Chilongozi; Clement Mapanje; Robert Krysiak; Syze Gama; Francis E A Martinson; Myron S Cohen Journal: J Infect Dis Date: 2006-12-22 Impact factor: 5.226
Authors: Matthew C Strain; Susan J Little; Eric S Daar; Diane V Havlir; Huldrych F Gunthard; Ruby Y Lam; Otto A Daly; Juin Nguyen; Caroline C Ignacio; Celsa A Spina; Douglas D Richman; Joseph K Wong Journal: J Infect Dis Date: 2005-03-29 Impact factor: 5.226
Authors: Pragna Patel; Jeffrey D Klausner; Oliver M Bacon; Sally Liska; Melanie Taylor; Anthony Gonzalez; Robert P Kohn; William Wong; Sydney Harvey; Peter R Kerndt; Scott D Holmberg Journal: J Acquir Immune Defic Syndr Date: 2006-05 Impact factor: 3.731
Authors: Frances H Priddy; Christopher D Pilcher; Renee H Moore; Pradnya Tambe; Mahin N Park; Susan A Fiscus; Mark B Feinberg; Carlos del Rio Journal: J Acquir Immune Defic Syndr Date: 2007-02-01 Impact factor: 3.731
Authors: Christopher D Pilcher; Susan A Fiscus; Trang Q Nguyen; Evelyn Foust; Leslie Wolf; Del Williams; Rhonda Ashby; Judy Owen O'Dowd; J Todd McPherson; Brandt Stalzer; Lisa Hightow; William C Miller; Joseph J Eron; Myron S Cohen; Peter A Leone Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: Christopher D Pilcher; Matthew A Price; Irving F Hoffman; Shannon Galvin; Francis E A Martinson; Peter N Kazembe; Joseph J Eron; William C Miller; Susan A Fiscus; Myron S Cohen Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: Christopher D Pilcher; George Joaki; Irving F Hoffman; Francis E A Martinson; Clement Mapanje; Paul W Stewart; Kimberly A Powers; Shannon Galvin; David Chilongozi; Syze Gama; Matthew A Price; Susan A Fiscus; Myron S Cohen Journal: AIDS Date: 2007-08-20 Impact factor: 4.177
Authors: Bernhard Kerschberger; Aung Aung; Qhubekani Mpala; Nombuso Ntshalintshali; Charlie Mamba; Michael Schomaker; Marie Luce Tombo; Gugu Maphalala; Dumile Sibandze; Lenhle Dube; Rufaro Kashangura; Simangele Mthethwa-Hleza; Alex Telnov; Roberto de la Tour; Alan Gonzalez; Alexandra Calmy; Iza Ciglenecki Journal: J Acquir Immune Defic Syndr Date: 2021-12-15 Impact factor: 3.771
Authors: Elena Dukhovlinova; Alexey Masharsky; Aleksandra Vasileva; Alessandro Porrello; Shuntai Zhou; Olga Toussova; Sergei Verevochkin; Ekaterina Akulova; Dmitrij Frishman; David Montefiori; Celia Labranche; Irving Hoffman; William Miller; Myron S Cohen; Andrei P Kozlov; Ronald Swanstrom Journal: AIDS Res Hum Retroviruses Date: 2018-07-30 Impact factor: 2.205
Authors: Jintanat Ananworanich; Leigh Anne Eller; Suteeraporn Pinyakorn; Eugene Kroon; Somchai Sriplenchan; James Lk Fletcher; Duanghathai Suttichom; Christopher Bryant; Rapee Trichavaroj; Peter Dawson; Nelson Michael; Nittaya Phanuphak; Merlin L Robb Journal: J Int AIDS Soc Date: 2017-06-26 Impact factor: 5.396
Authors: Maartje Dijkstra; Godelieve J de Bree; Ineke G Stolte; Udi Davidovich; Eduard J Sanders; Maria Prins; Maarten F Schim van der Loeff Journal: BMC Infect Dis Date: 2017-06-14 Impact factor: 3.090
Authors: Eugène D M B Kroon; Nittaya Phanuphak; Andrew J Shattock; James L K Fletcher; Suteeraporn Pinyakorn; Nitiya Chomchey; Siriwat Akapirat; Mark S de Souza; Merlin L Robb; Jerome H Kim; Frits van Griensven; Jintanat Ananworanich; David P Wilson Journal: J Int AIDS Soc Date: 2017-06-28 Impact factor: 5.396
Authors: Eduard J Sanders; Oscar Chirro; Clifford Oduor; Juma Mangi; Elizabeth Wahome; Matthew A Price; Hubert C Gelderblom; Elisabeth M van der Elst; Susan M Graham Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Jintanat Ananworanich; Carlo P Sacdalan; Suteeraporn Pinyakorn; Nicolas Chomont; Mark de Souza; Tassanee Luekasemsuk; Alexandra Schuetz; Shelly J Krebs; Robin Dewar; Linda Jagodzinski; Sasiwimol Ubolyam; Rapee Trichavaroj; Sodsai Tovanabutra; Serena Spudich; Victor Valcour; Irini Sereti; Nelson Michael; Merlin Robb; Praphan Phanuphak; Jerome H Kim; Nittaya Phanuphak Journal: J Virus Erad Date: 2016
Authors: Susan M Graham; Clara Agutu; Elise van der Elst; Amin S Hassan; Evanson Gichuru; Peter M Mugo; Carey Farquhar; Joseph B Babigumira; Steven M Goodreau; Deven T Hamilton; Thumbi Ndung'u; Martin Sirengo; Wairimu Chege; Eduard J Sanders Journal: JMIR Res Protoc Date: 2020-08-07